anti-Nipah_265
| anti-Nipah_ID | anti-Nipah_265 |
| anti-Nipah Drug | 4-nitro-2-[(2-phenylacetyl)amino]benzamide |
| Nipah virus strain | NiV (Nipah G/F fusion expression vector) |
| Approaches used to test anti-Nipah activity | Experimental |
| Methods used to test anti-Nipah activity | In-vitro |
| Models used to test anti-Nipah activity | Vero |
| Mode of infection to test anti-Nipah activity | Transfection |
| Viral titer to test anti-Nipah activity | NA NA |
| Mode of Drug delivery for anti-Nipah activity | Culture |
| Time of Drug delivery for anti-Nipah activity | Post transfection |
| Duration of Drug delivery for anti-Nipah activity | 24 hours |
| Drug concentration used to test anti-Nipah activity | 20 μM |
| Assays used to test anti-Nipah activity | Syncytia formation |
| anti-Nipah activity | No significant difference [Fusion Inhibition (10 %)] |
| References | Singethan K, Hiltensperger G, Kendl S, Wohlfahrt J, Plattet P, Holzgrabe U, Schneider-Schaulies J N-(3-Cyanophenyl)-2-phenylacetamide, an effective inhibitor of morbillivirus-induced membrane fusion with low cytotoxicity. J Gen Virol. 2010 Nov;91(Pt 11):2762-72. doi: 10.1099/vir.0.025650-0 |
| Comments | N-(3-cyanophenyl)-2-phenylacetamide (compound 1) has a high capacity to inhibit MV- and CDV-induced (IC(50) _M), but not NiV-induced, membrane fusion. Findings demonstrated that this compound is a most applicable inhibitor of morbillivirus-induced membrane fusion in tissue culture experiments including highly sensitive primary cells. |